Navigation Links
Survival shortened when ER/PR negative breast cancer spreads to the brain
Date:12/17/2007

SAN ANTONIO − Two studies from Mayo Clinics site in Jacksonville, Fla., of women whose breast cancer spread to their brain, have found that women whose tumors do not have estrogen or progesterone receptors have the worst overall outcomes. Because of this, these patients should be treated aggressively after an initial diagnosis to help prevent such a metastasis, say the investigators, who presented their findings at the San Antonio Breast Cancer Symposium.

Those cancers include so-called triple negative tumors cancer that does not exhibit HER2 growth factors or estrogen (ER) or progesterone receptors (PR) as well as HER2 positive cancers that are also ER/PR negative, say Mayo investigators.

This research is the first to look at differences in brain metastases and survival by different breast cancer subtypes. In one of the studies led by Stephanie Hines, M.D., investigators found that the median survival from diagnosis to death in women with triple negative tumors with brain metastases was 26 months, compared to 49 months in women with other types of breast cancer brain metastasis.

The second study, led by Laura Vallow, M.D., looked only at HER2+ tumors that had spread to the brain, and concluded that median survival from initial diagnosis to death in patients with ER/PR- tumors was only 17.5 months, compared to 55 months for women with ER/PR+ cancer.

We need to be aware that this kind of cancer is high risk and we should do all that we can to prevent brain metastasis, says Dr. Hines. For women with triple negative breast cancer, improvements in outcome will likely come when new treatments for this type of cancer are successfully developed.

Targeted therapies are available for cancers that are ER/PR+ or HER2+ before they metastasize to the brain. Herceptin, which treats HER2+ cancer, is theorized to be too large to breach the blood-brain barrier, and patients who have triple negative or HER2+ ER/PR breast cancer do not have targeted therapies. Whats needed, therefore, are treatments for HER2+ and triple negative tumors that can reach the brain, as well as treatments that are specifically targeted to treat triple negative breast cancer cells, Dr. Hines says.

Metastatic breast cancer accounts for 20 percent to 30 percent of the 170,000 cases of brain metastases diagnosed annually, and as improvements in systemic therapy prolong survival, brain metastasis in breast cancer patients is becoming more evident, says Dr. Vallow. These results suggest that more aggressive therapy in ER/PR- tumors may be warranted because patients with ER/PR- disease tend to develop brain metastasis even if the cancer has not spread anywhere else, and this metastasis develops sooner and survival is shorter compared to breast cancer that is ER/PR positive, she says.

While the outcome looks worse for HER2+/ER/PR- tumors than for triple negative cancers, findings from the two studies cannot be matched against each other because the studies did not directly compare these two groups of patients against each other. One compared triple negative cancers against all other subtypes, and the other compared HER2+/ER/PR+ cancers against HER2+/ER/PR- cancers, Dr. Hines says. We didnt directly compare outcomes from triple negative tumors against HER2+ ER/PR- cancer.

For now, what we can say is that both the triple negative group and the HER2 + ER/PR- groups appear to have a poor outcome, which is unfortunate, she says.

The studies looked at women treated for breast cancer at Mayo Clinic Jacksonville from 1993 to 2007 (Hines study) or from 1996 to 2006 (Vallow study) whose cancer spread to the brain.

Dr. Hines found in a study of 103 patients that those with triple negative tumors developed systemic and brain metastasis sooner than patients with other types of breast cancer, and had significantly shorter survival overall. Specifically, investigators concluded that time from:

  • Diagnosis to distant metastasis was a median of 15 months in the triple negative group versus 24 months in the rest of the patients.
  • Distant metastasis to brain metastasis was a median of three months for triple negative cancer versus 11 months for other subtypes.
  • Brain metastasis to death, on average, was the same in both groups seven months presumably because the tumors, once in the brain, were treated alike, with whole brain radiation, stereotactic radiosurgery, and /or surgery, despite their tumor subtype.
  • Diagnosis to death was a median of 26 months in the triple negative patients versus 49 months in other patients.

Dr. Vallow and her team of researchers looked at data from 83 women whose HER2+ tumors had spread to their brains. They found that:

  • Patients with ER/PR- tumors were more likely to have brain metastasis as the first site of disease progression (73 percent) compared to women with ER/PR+ cancer (27 percent).
  • Time from diagnosis to brain metastasis was a median of 45 months in ER/PR+ tumors compared to 14.5 months in ER/PR- cancer.
  • Time from brain metastasis to death was a median 10 months in women with ER/PR+ tumors compared to 3 months in patients with ER/PR- cancer.
  • Median survival for the ER/PR+ patients was 55 months compared with 17.5 months in patients with ER/PR- cancer.

This study shows us that the outcome of HER2 patients with brain metastasis tended to be worse for those women with ER/PR negative status, however, because this study was small, more patients need to be studied to confirm this finding, Dr. Vallow says.


'/>"/>

Contact: Paul Scotti
scotti.paul@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
4. Human C-reactive protein regulates myeloma tumor cell growth and survival
5. Mediterranean Diet May Boost Alzheimers Survival
6. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
7. The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival
8. Communication in cancer world is key to survival
9. Molecular profiling can accurately predict survival in colon cancer patients
10. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
11. Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and thank ... Every day, two kidneys filter about 120 to 150 quarts of blood. Put another ... regulating fluid levels and blood pressure, supporting bone health and promoting red blood cell ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced ... The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive ... that have excellent programs for the delivery and improvement of disease management and ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... educational training program owned and organized by HMP Communications Holdings, LLC, today announced ... for physicians within its nationwide network of wound centers interested in becoming Certified ...
(Date:3/23/2017)... CO (PRWEB) , ... March 23, 2017 , ... ... serving the families and businesses of the greater Fort Collins area, has unveiled ... in their ongoing community involvement program. Donations to this worthy cause may now ...
(Date:3/23/2017)... ... , ... After raising more than $1.135 million ($1,479,231 AUD) from nearly 20,000 ... in crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle USA, ... “We’re excited to be operating on U.S. shores, where most of our initial crowdfunding ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017  The U.S. Food ... (avelumab) for the treatment of adults and pediatric patients ... (MCC), including those who have not received prior chemotherapy. ... a rare, aggressive form of skin cancer. ... cancers, patients with a rare form called Merkel cell ...
(Date:3/23/2017)... DIEGO and VANCOUVER, British Columbia ... (NASDAQ: SPHS ) (the "Company" or "Sophiris"), ... the treatment of urological diseases, today announced that data ... evaluated the drug as a focal treatment for localized ... March 26, 2017 at the 32 nd Annual ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... Devices Market 2017-2021" report to their offering. ... The global oxygen therapy devices ... 2017-2021. The report, Global Oxygen Therapy Devices Market ... inputs from industry experts. The report covers the market landscape and ...
Breaking Medicine Technology: